Search results
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as sodium monohydrate). Excipients with known effect: Contains 154.6 mg anhydrous lactose (equivalent to 162.75 mg lactose monohydrate).
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as ibandronic sodium monohydrate). Excipients: Contains 162.75 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3.
Bonviva 150 mg is indicated for the prevention of osteoporosis in postmenopausal women who are not yet osteoporotic, but are at increased risk for fractures as defined in the current national Clinical Guidelines
Bonviva is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of developing bone fractures (breaks). Its effect in reducing the risk of spine fractures has been shown in studies, but its effect on the risk of fractures of the neck of the femur (the top of the thighbone ...
Bonviva 3 mg every 3 months i.v. is in patients 2.4 Warnings and Precautions 2.4.1 General Bonviva other bisphosphonates y may cause a in serum other of bone be ef before starting Bonviva injection therapy. intake of vitamin D is important in patients. Patients must receive vitamin D. Bonviva 3 mg every 3 months i.v. is not for use in patients ...
Bonviva is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures. Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause. At the menopause, a woman’s ovaries stop producing the female hormone, oestrogen, which helps to keep her skeleton healthy.
Na stronie m.in. opis działania, wskazania, skład, zamienniki oraz opinie pacjentów.Bonviva to lek z grupy bisfosfonianów, który zawiera substancję czynną - kwas ibandronowy. Jest stosowany w leczeniu osteoporozy u kobiet po menopauzie, ze zwiększonym ryzykiem złamań.
